The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viruses (AAVs) have been used widely for in vivo gene therapy. However, adaptive immune responses to AAV have posed a significant hurdle in clinical application of AAV vectors. Recent advances have suggested a crucial role for innate immunity in shaping adaptive immune responses. How AAV activates innate immunity, and thereby promotes AAV-targeted adaptive immune responses, remains unknown. Here we show that AAV activates mouse plasmacytoid DCs (pDCs) via TLR9 to produce type I IFNs. In vivo, the TLR9-MyD88 pathway was crucial to the activation of CD8+ T cell responses to both the transgene product and the AAV capsid, leading to loss of transgene expression and the generation of transgene product-specific and AAV-neutralizing antibodies. We further demonstrate that TLR9-dependent activation of adaptive immunity targeting AAV was mediated by type I IFNs and that human pDCs could be activated in vitro to induce type I IFN production via TLR9. These results reveal an essential role for the TLR9-MyD88-type I IFN pathway in induction of adaptive immune responses to AAV and suggest that strategies that interfere with this pathway may improve the outcome of AAV-mediated gene therapy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Myd88−/− mice that development of CD8+ T cell responses against rh32.33 capsid depended on MyD88(15, 17) (Fig. 2A, middle panel).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Tlr9−/− and Myd88−/− mice that the innate immune response to self-complementary AAV was indeed dependent on the TLR9/MyD88 pathway (Fig. 1D and 1E), as previously shown in the literature (15–17).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia are the chief resident immune cells of the retina and are capable of inducing pro-inflammatory cytokine expression through TLR9- and TLR2-mediated responses,41 which have been demonstrated to detect AAV genomes and capsids, respectively.42, 43, 44”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unmethylated CpG elements elicit innate immunity and CTL response through TLR9/MyD88-dependent pathway (23).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous animal studies have shown the immune-activating effects of CpG motifs in AAV (23, 150, 151).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., & Schmitz, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6037 · Cited by 1,298
Cited by
Items 101–200 of 345
Harun‐Or‐Rashid, M., Pappenhagen, N., Zubricky, R. D., Coughlin, L., Jassim, A. H., & Inman, D. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104944 · Cited by 65
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“IFN-a/b, along with IL-12, can activate CD8 T cells to produce IFN-g [74,90].”
BackgroundInfluentialFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 67
Gardner, M. R., Fetzer, I., Kattenhorn, L. M., Davis-Gardner, M. E., Zhou, A. S., Alfant, B., Weber, J. A., Kondur, H. R., Martinez-Navio, J. M., Fuchs, S. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.004 · Cited by 60
Brown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 60
“Shaping the tropism of existing AAVs to the needs of a specific disease has the potential to reduce activation of the immune system by detargeting cell types, such as dendritic cells, that have an increased ability to activate T-cells (Herzog et al., 2019; Rogers et 45 al., 2017; Rossi et al., 2019; Somanathan et al.,…”
BackgroundImmunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“Although the full clinical significance of innate response to rAAV is unclear (18), unmethylated CpG motifs in rAAV vector genome interact with toll-like receptor (TLR) 9 present in plasmacytoid dendritic cells and Kupffer cells, releasing type I interferons activating cellular and humoral responses in mouse models (1…”
BackgroundMyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Alternatively, since CpG elements are recognized by TLR9 (23), inhibition of TLR9 recognition can be also used to reduce CpG-activated cellular immunity.”
BackgroundInfluentialHerzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“skeletal muscle (66-68) (reviewed in (69)).”
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Hudry, E., Aihara, F., Meseck, E. K., Mansfield, K. G., McElroy, C., Chand, D. H., Tukov, F. F., & Penraat, K. A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.020 · Cited by 54
Recent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 62
Somanathan, S., Breous, E., Bell, P., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.40 · Cited by 54
Gene Therapy Developments for Pompe Disease
Unnisa, Z., Yoon, J. K., Schindler, J. W., Mason, C., & van Til, N. P. (2022) · Biomedicines · doi:10.3390/biomedicines10020302 · Cited by 61
“The pivotal role of TLR9 activation [93] as a mediator of both the cellular and humoral immune response needs to be analyzed further, as well as CpG motifs in the vector genome, which can drive the immune responses associated with CD8+ T-cell activation [94].”
BackgroundBurdett, T., & Nuseibeh, S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00363-0 · Cited by 61
“Similarly, the increase in AAV8 selection is coupled with an increase in products targeting the liver via systemic administration due to the ability of AAV8 to achieve robust liver transduction [45].”
BackgroundHandyside, B., Ismail, A. M., Zhang, L., Yates, B., Xie, L. Y., Sihn, C., Murphy, R., Bouwman, T., Kim, C. K., Angelis, R. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.001 · Cited by 54
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“22 Furthermore, the study found TLR9 signaling to be requisite to subsequent CD8 + T cell responses to the transgene product.”
Treating Parkinson’s disease by astrocyte reprogramming: Progress and challenges
Wei, Z. D., & Shetty, A. K. (2021) · Science Advances · doi:10.1126/sciadv.abg3198 · Cited by 54
Activation of the Cellular Unfolded Protein Response by Recombinant Adeno-Associated Virus Vectors
Balakrishnan, B., Sen, D., Hareendran, S., Roshini, V., David, S., Srivastava, A., & Jayandharan, G. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053845 · Cited by 50
“In AAV2 mediated gene therapy, the concept of capsid protein dependent immunotoxicity is well documented [5,34] and several groups have shown that cellular cytoplasmic surveillance mechanisms such as the NF-kB signalling [35], MYD88 pathway or toll-like receptor (TLR-9) [36,37] signalling influence this process.”
BackgroundChandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
“Intramuscular injection of recombinant AAV in wildtype mice elicited TLR9-mediated activation of pDCs and a type I interferon response independent of AAV serotype, suggesting that the TLR9-Myd88 pathway was critical for the activation of a CD8+ T cell response against the AAV capsid and transgene [107].”
BackgroundSuzuki, M., Bertin, T. K., Rogers, G. L., Cela, R. G., Zolotukhin, I., Palmer, D. J., Ng, P., Herzog, R. W., & Lee, B. (2013) · Molecular Therapy · doi:10.1038/mt.2012.277 · Cited by 49
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
“Innate immune sensing of AAV vectors depends on TLR9 and is increased with scAAV due to increased TLR9 signaling from these vectors [13,15].”
BackgroundResultTomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 47
Chung, C.-H., Murphy, C. M., Wingate, V. P. M., Pavlicek, J. W., Nakashima, R., Wei, W., McCarty, D. M., Rabinowitz, J. E., & Barton, E. S. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.002 · Cited by 49
Mitochondrial DAMPs: Key mediators in neuroinflammation and neurodegenerative disease pathogenesis
Yu, H., Ren, K., Jin, Y., Zhang, L., Liu, H., Huang, Z., Zhang, Z., Chen, X., Yang, Y., & Wei, Z. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110217 · Cited by 51
Self-citationRegulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
“1 Now, it is known that they are able to trigger an innate immune response through Toll-like receptor (TLR) signaling pathways 58 as well as transduce DC in vitro 59–61 and in vivo.”
Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“14 Moreover, the authors reported that the anti-HA and anti-capsid humoral responses were also significantly diminished in both models.”
Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy
Brimble, M. A., Winston, S. M., & Davidoff, A. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.025 · Cited by 45
“49 As previously demonstrated, contaminating sequences can be packaged in fully functional vector particles capable of transducing cells. rAAV transduction is known to activate the innate, DNA-recognizing, TLR9/MyD88 pathway, 50 and CpG motifs are known to be recognized by TLR9.”
BackgroundAdvances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Oakland, M., Sinn, P. L., & McCray, P. B. (2012) · Molecular Therapy · doi:10.1038/mt.2012.32 · Cited by 51
Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown, N. J., Song, L., Rao, K. N., & Hirsch, M. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.038 · Cited by 43
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“It has been shown that the TLR9–MyD88 pathway is crucial for cross priming AAV capsid-specific CD8+ T cells, a process that requires the cooperation of both pDC and cDC subsets of dendritic cells, as well as for activating transgene-specific CD8+ T cell responses (31, 32).”
BackgroundErtl, H. C. J. (2023) · Drugs · doi:10.1007/s40265-023-01836-1 · Cited by 43
Herzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
“CD8 T cell responses to the transgene product are dependent on endosomal sensing of the AAV genome by TLR9, which rapidly induces type I interferon (IFN) and pro-inflammatory cytokine expression [17, 18].”
Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
“Both tlr9−/− and myd88−/− mice showed absence of adaptive responses to AAV (13, 14).”
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Synthetic immunomodulation with a CRISPR super-repressor in vivo
Moghadam, F., LeGraw, R., Velazquez, J. J., Yeo, N. C., Xu, C., Park, J. H., Chavez, A., Ebrahimkhani, M. R., & Kiani, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0563-3 · Cited by 40
Baruteau, J., Cunningham, S. C., Yılmaz, B. Ş., Perocheau, D. P. B., Eaglestone, S., Burke, D. G., Thrasher, A. J., Waddington, S. N., Lisowski, L., Alexander, I. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.005 · Cited by 40
“AAV vectors with a single-stranded (ss)DNA genome are able to stimulate the innate immune system through the Tolllike receptor (TLR)9/myeloid differentiation primary response gene 88 (MyD88) and type I IFN cascades.(33) However, only a mild and highly transient immune response has been observed for ssAAVs regardless o…”
BackgroundHarkins, A. L., Ambegaokar, P. P., & Keeler, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00435 · Cited by 39
“Although AAV does not robustly stimulate the innate immune system, unmethylated CpG sequences within the AAV genome can stimulate TLR9 [4], as well as capsids by TLR2 [5].”
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Activation of the human immune system via toll‐like receptors by the oncolytic parvovirus H‐1
Sieben, M., Schäfer, P., Dinsart, C., Galle, P. R., & Moehler, M. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27938 · Cited by 35
“Furthermore, TLR9 dependent signaling has also been implicated in infections with a variety of viruses including MCMV, HSV-1 and -2 and adeno-associated-virus (AAV-1, -2, -9).(30,31,39,40) If TLRs are involved in recognition of H-1PV, their activation should lead to changes in the expression and activity of NFjB.”
BackgroundModifying immune responses to adeno-associated virus vectors by capsid engineering
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., et al. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.015 · Cited by 34
“The involvement of TLR9 in the development of antibodies directed against AAV is unclear; conflicting results exist in the mber 2023 literature.20,33,34,42 However, there is clear evidence for the importance of MyD88 in B cells for antibody generation.33,34 Therefore, targeting MyD88 might be more promising than focus…”
BackgroundInfluentialGene therapy vector-related myocarditis
Silver, E., Argirò, A., Hong, K. N., & ADLER, E. D. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131617 · Cited by 36
Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Seregin, S. S., & Amalfitano, A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797247578 · Cited by 39
“TLR9-KO and MyD88-KO mice had diminished (at least 10 fold) production of IFN by CD8 T cells, as well reduced titers of AAV2 neutralizing antibodies at 12-26 weeks post IM injection of AAV2 vectors [117].”
BackgroundHayashita‐Kinoh, H., Yugeta, N., Okada, H., Nitahara‐Kasahara, Y., Chiyo, T., Okada, T., & Takeda, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.5 · Cited by 37
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“There is an emerging picture from mice data that AAV vectors activate the innate immune response through the TLR9 pathway including MyD88, which in turn promotes the adaptive anti-AAV capsid CD8 T cells’ immune response [33-36].”
BackgroundOcular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Self-citationCosta-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
“Previous work had identi fi ed TLR9, which recognizes unmethylated CpG sequences present in viral or bacterial but not mammalian DNA, as the sensor involved in the induction oftype I IFN responses in pDCs 20,22 .”
Self-citationHepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“The innate immunity response in rAAV may be responsible for the early adverse events a week after GT administration [41–43].”
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
“24 – 26 Furthermore, co-stimulation by CD4 + T cells is crucial.”
Strategies to improve safety profile of AAV vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1054069 · Cited by 33
“CpG motifs are often unmethylated in AAV vectors, despite the production in mammalian cells, and the activation of the TLR9-MyD88 signalling pathway by unmethylated CpG has been shown to promote adaptive immune responses not only against the capsid but also the transgene (Zhu et al., 2009).”
BackgroundSelot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“[68] used adoptive transfer of AAV infected dendritic cells (DC)s into normal C57BL/6 and CD40 ligand deficient CD40L(-/-) mice to demonstrate the role of CD40 ligand in antigen presentation and CTL activation.”
Gene Transfer Therapy for Neurodevelopmental Disorders
Özlü, C., Bailey, R. M., Sinnett, S. E., & Goodspeed, K. (2021) · Developmental Neuroscience · doi:10.1159/000515434 · Cited by 34
Gardner, M. R. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00176 · Cited by 31
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
Paglino, J. C., Andres, W., & van den Pol, A. N. (2014) · Journal of Virology · doi:10.1128/jvi.03508-13 · Cited by 36
“TLR-9 mediated an IFN response to wild-type AAV in murine and human pDCs (56), consistent with results for autonomous parvoviruses in hPBMCs (23) but in contrast to the absence of a response to MVMp seen by Mattei et al.”
ResultDudek, A. M., & Porteus, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660302 · Cited by 32
Chen, N., Sun, K., Chemuturi, N. V., Cho, H., & Xia, C. Q. (2022) · The AAPS Journal · doi:10.1208/s12248-021-00678-7 · Cited by 31
“The activation of both the TLR2 and the TLR9 pathway can be inferred from the secreted levels of these effector molecules (pro-inflammatory cytokines) (45, 46).”
BackgroundCastillo‐Rodríguez, R. A., Arango-Rodríguez, M. L., Escobedo, L., Hernández-Baltazar, D., Gompel, A., Forgez, P., & Martínez‐Fong, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097151 · Cited by 30
“This property of NTS-polyplex nanoparticles remains important considering the concerns with potential immune reactions to lipoplexes and viral vectors [33,34], and potential oncogenicity of viral vectors able to integrate the transgene into the host genome [35,36].”
BackgroundAdeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
Mingozzi, F., & Büning, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00120 · Cited by 31
“Conversely, following tail vein injection, neither a TLR-2, nor a TLR-9, or a type I IFN dependent induction of AAV specific IgG antibodies could be detected (15, 18).”
BackgroundMethodImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
Grekova, S. P., Zawatzky, R., Hörlein, R., Cziepluch, C., Mincberg, M., Davis, C. A., Rommelaere, J., & Daeffler, L. (2009) · Journal of Virology · doi:10.1128/jvi.01618-09 · Cited by 28
“However, several parvoviruses, including Kilham rat virus (60) and adeno-associated virus 1 (AAV-1), -2, and -9 (59), were shown to stimulate TLR9 through their ssDNA genomes.”
BackgroundMoreau, A., Vandamme, C., Segovia, M., Devaux, M., Guilbaud, M., Tilly, G., Jaulin, N., Duff, J. L., Chérel, Y., Deschamps, J., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.28 · Cited by 28
Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice
Hernández, M. E., Rembao, J. D., Hernández-Baltazar, D., Castillo‐Rodríguez, R. A., Téllez-López, V. M., Flores-Martinez, Y. M., Orozco-Barrios, C. E., Rubio-Zapata, H., Sánchez-García, A. D. C., Ayala-Dávila, J., et al. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.11.013 · Cited by 27
“In this regard, polyplexes have a low toxicity and weak influence on the innate immune responses(26) in comparison to lipoplexes and viral gene vectors.(29,30) To date, the safety of NTS-polyplex NPs administration has not yet been evaluated.”
BackgroundHutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Bucher, K., Rodríguez‐Bocanegra, E., Wissinger, B., Straßer, T., Clark, S. J., Birkenfeld, A. L., Siegel-Axel, D. I., & Fischer, M. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-28830-7 · Cited by 28
Coroadinha, A. S. (2023) · Cells · doi:10.3390/cells12050732 · Cited by 27
Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes
Ferriero, R., Bruno, G., Padula, A., Pisano, S., Boffa, I., Gargaro, M., Imperatore, T., Battipaglia, M., Vivenzio, S., Perna, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57382-9 · Cited by 26
“Toll-like receptor engagement by AAV components in macrophages, DCs, and liver ECs leads to the generation of anti-AAV cytotoxic CD8 + T cells and antibodies 42 – 46 .”
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“Several models have demonstrated that the TLR9 pathway may be involved in loss of the vector transgene [128, 129].”
BackgroundCovert Warfare Against the Immune System: Decoy Capsids, Stealth Genomes, and Suppressors
Hoffman, B. E., & Herzog, R. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.176 · Cited by 25
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“The TLR9-initiated pathway is a well-recognised component of the pro-inflammatory response to AAV-mediated gene therapy in the retina (Chan et al., 2021b) and elsewhere in the body (Zhu et al., 2009; Martino et al., 2011; Faust et al., 2013).”
Lotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 28
Enhancers of Adeno-associated Virus AAV2 Transduction via High Throughput siRNA Screening
Wallen, A. J., Barker, G. A., Fein, D. E., Jing, H., & Diamond, S. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.4 · Cited by 25
Gil-Fariña, I., Scala, M. D., Vanrell, L., Olagüe, C., Vales, Á., High, K. A., Prìeto, J., Mingozzi, F., & González‐Aseguinolaza, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067748 · Cited by 26
“AAV intramuscular injection induces signaling through the Toll-like receptor 9 (TLR9)–myeloid differentiation factor 88 (MyD88) pathway to induce type I IFN and this activation is critical for CD8+ T cell responses to the AAV capsid and for the loss of transgene expression in vivo [6].”
MethodEspadas-Álvarez, A. J., Bannon, M. J., Orozco-Barrios, C. E., Escobedo, L., Ayala-Dávila, J., Reyes-Corona, D., Soto-Rodríguez, G., Escamilla‐Rivera, V., Vizcaya‐Ruíz, A. D., Gutiérrez-Castillo, M. E., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.02.006 · Cited by 24
Recombinant adeno-associated virus vectors in the treatment of rare diseases
Hastie, E. L., & Samulski, R. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1039511 · Cited by 25
Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Yang, L., & Xiao, X. (2013) · Virology Journal · doi:10.1186/1743-422x-10-50 · Cited by 24
“Furthermore, the AAV vector itself elicits only a relatively weak innate and acquired immune response in the hosts [5], which affirms the tolerated transgene expression and the higher safety profile in gene therapy.”
BackgroundSuriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.036 · Cited by 21
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
Gardner, M. R., & Farzan, M. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000367 · Cited by 22
Struebing, F. L., Wang, J., Li, Y., King, R., Mistretta, O. C., ENGLISH, A. W., & Geisert, E. E. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00354 · Cited by 21
“The shRNA target sequence was previously validated and is described in (Zukor et al., 2013).”
MethodLéger, A., Guiner, C. L., Nickerson, M. L., McGee, K., Ferry, N., Moullier, P., Snyder, R. O., & Penaud‐Budloo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020881 · Cited by 23
“demonstrated that the TLR9-MyD88 pathway was involved in the activation of CD8+ T cell responses to both the transgene product and the rAAV2 capsid, leading to loss of transgene expression [42].”
BackgroundBioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics: Regulatory Expectations
Gorovits, B., Marshall, J.-C. A., Smith, J., Whiteley, L. O., & Neubert, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0135 · Cited by 22
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain
Hopp, S. C., Bihlmeyer, N. A., Corradi, J. P., Vanderburg, C., Cacace, A. M., Das, S., Clark, T. W., Betensky, R. A., Hyman, B. T., & Hudry, E. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14469 · Cited by 20
“Other literature reports immune pathways activated by AAV (McCaffrey et al. 2008; Zhu et al. 2009), although the AAV host responses likely vary upon the serotype, the injection route and the transduced cells.”
BackgroundChen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
“Our data corroborate previous studies’ findings using C3 [37] and MyD88 mice [34, 36].”
ResultTriozzi, P. L., Aldrich, W. A., & Ponnazhagan, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.086 · Cited by 20
Delivery of Antigens by Viral Vectors for Vaccination
Krause, A., & Worgall, S. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.84 · Cited by 21
Laredj, L. N., & Beard, P. (2011) · Journal of Virology · doi:10.1128/jvi.05407-11 · Cited by 21
“showed that AAV1, -2, and -9 stimulate TLR9 through their ssDNA genomes in murine immune cells (50).”
BackgroundInfluentialImmunology of Retinitis Pigmentosa and Gene Therapy–Associated Uveitis
Yang, P. G., Mustafi, D., & Pepple, K. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041305 · Cited by 22
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
Li, L., Vasan, L., Kartono, B., Clifford, K. P., Attarpour, A., Sharma, R., Mandrozos, M., Kim, A., Zhao, W., Belotserkovsky, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102725 · Cited by 20
Notarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 21
“32 Intracellular TLR9 may detect the vector genome during the endosomal trafficking of AAV, potentially due to viral uncoating or damage to viral particles and partial viral DNA release.”
BackgroundViral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Raykov, Z., Grekova, S. P., Hörlein, R., Leuchs, B., Giese, T., Giese, N. A., Rommelaere, J., Zawatzky, R., & Daeffler, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055086 · Cited by 22
“cells [33,64].”
Vila, M. C., Novak, J. S., Klimek, M. B., Li, N., Morales, M., Fritz, A. G., Edwards, K. A., Boehler, J., Hogarth, M. W., Kinder, T. B., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5263 · Cited by 21
“For example, apart from eliciting pro-inflammatory NF-κB activation, the AAV vectors also interact with the innate immune system via the single-stranded DNA genome and Toll-like receptor (TLR) 9/MyD88 and type I interferon pathways [37,38] and induce capsid-specific T-helper 1 antibody responses [39].”
BackgroundCapsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy
Franke, A., Hardet, R., Prager, L., Bentler, M., Demeules, M., John-Neek, P., Jäschke, N. M., Ha, T. C., Hacker, U. T., Adriouch, S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.010 · Cited by 18
Elkouby, L., Armour, S. M., Toso, R., DiPietro, M. A., Davidson, R. J., Nguyen, G. N., Willet, M., Kutza, S., Silverberg, J., Frick, J. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.005 · Cited by 20
“Molecular Therapy: Methods TLR9 signaling after gene transfer via reducing the amount of CpG dinucleotides from the coding sequence and thus minimize potential innate immune responses against the vector.(27) Administration of the different codon-optimized constructs into a hemophilic mouse model demonstrated a range o…”
Background
Metadata
- Authors
- Zhu, J., Huang, X., & Yang, Y.
- Affiliations
- Duke Medical Center (US)
- Duke University (US)
- Corresponding author
- Yang, Yiping
- Venue
- Journal of Clinical Investigation
- Published
- 2009-08-03
- Volume
- 119
- Issue
- 8
- Pages
- 2388-2398
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2719948
- OpenAlex
- W2043149070
- Semantic Scholar
- 9808ef8c0218096852d97ab403f3e3a9feeb2215
- Cited by
- 330
- References
- 73
- Citations by year
- 2026: 23 · 2025: 20 · 2024: 26 · 2023: 31 · 2022: 29 · 2021: 27 · 2020: 29 · 2019: 24 · 2018: 16 · 2017: 17 · 2016: 7 · 2015: 15 · 2014: 10 · 2013: 15 · 2012: 11
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA047741)
- University of North Carolina at Chapel Hill
- National Cancer Institute (CA111807, CA047741, P01CA047741, R01CA111807)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV gene therapy, TLR9, MyD88, type I interferon, plasmacytoid dendritic cells, innate immunity, adaptive immune response, CD8+ T cells, AAV capsid, neutralizing antibodies, transgene expression, immunogenicity
- MeSH terms
- Dependovirus, Animals, Cells, Cultured, Dendritic Cells, Genetic Vectors, Humans, Immunity, Innate, Interferon Type I, Mice, Inbred BALB C, Mice, Inbred C57BL, Genetic Therapy, Signal Transduction, CD8-Positive T-Lymphocytes, Transgenes, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.